Effects of different anti-asthmatic agents on induced sputum and eosinophil cationic protein in mild asthmatics

Respirology

Volumn 9, Issue 4, 2004, Pages 514-520

  Basyigit, Ilknur ^a   Yildiz, Fusun ^a,b   Ozkara, Sevgiye Kacar ^a   Boyaci, Hasim ^a   Ilgazli, Ahmet ^a   Ozkarakas, Oktay ^a  

^a KOCAELI UNIVERSITY   (Turkey)

^b NONE   (Turkey)

Author keywords

Asthma; Induced sputum; Inhaled corticosteroid; Leukotriene receptor antagonist; Theophylline

Indexed keywords

BUDESONIDE; CORTICOSTEROID; EOSINOPHIL CATIONIC PROTEIN; LEUKOTRIENE RECEPTOR BLOCKING AGENT; THEOPHYLLINE; ZAFIRLUKAST;

ADULT; ARTICLE; ASTHMA; CELL COUNT; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DRUG EFFECT; DRUG TOLERABILITY; EOSINOPHIL; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INHIBITION KINETICS; LUNG FUNCTION TEST; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SPUTUM EXAMINATION; SPUTUM LEVEL; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADULT; ANTI-ASTHMATIC AGENTS; ASTHMA; BLOOD CELL COUNT; EOSINOPHIL CATIONIC PROTEIN; EOSINOPHILS; FEMALE; HUMANS; LEUKOTRIENE ANTAGONISTS; MALE; RESPIRATORY FUNCTION TESTS; SPUTUM; THEOPHYLLINE; TRANSAMINASES; TREATMENT OUTCOME;

EID: 13144256701     PISSN: 13237799     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2004.00631.x     Document Type: Article

References (33)

1. Löwhagen O. Asthma and asthma-like disorders. Respir. Med. 1999; 93: 851-5.
2. Larsen JS, Jackson SK. Antileukotriene therapy for asthma. Am. J. Health Syst. Pharm. 1996; 53: 2821-30.
3. Barnes NC. The role of leukotriene receptor antagonists in the management of asthma. Eur. Respir. Rev. 1998; 8: 356-7.
4. Holgate ST, Bradding P, Sampson AP. Leukotriene antagonists and synthesis inhibitors: new directions in asthma therapy. J. Allergy Clin. Immunol. 1996; 98: 1-13.
5. Adachi M, Minoguchi K, Mita S et al. Effect of slow release theophylline on airway inflammation in bronchial asthma. Arerugi 1998; 47: 734-43. Japanese.
6. Aizawa H, Iwanaga T, Inoue H et al. Once-daily theophylline reduces serum eosinophil cationic protein and eosinophil levels in induced sputum of asthmatics. Int. Arch. Allergy Immunol 2000; 121: 123-8.
7. Pizzichini E, Pizzichini MM, Efthimiadis A et al. Indices of airway inflammation in induced sputum: reproducibility and validity of cell and fluid-phase measurements. Am J. Respir. Crit. Care Med. 1996; 154: 308-17.
8. Balzano G, Stefanelli F, Iorio C et al. Eosinophilic inflammation in stable chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1999; 160: 1486-92.
9. Pin I, Gibson PG, Kolendowicz R et al. Use of induced sputum cell counts to investigate airway inflammation in asthma. Thorax 1992; 47: 25-9.
10. Popov T, Gottschalk R, Kolendowicz R, Dolovich J, Powers P, Hargreave FE. The evaluation of a cell dispersion method of sputum examination. Clin. Exp. Allergy 1994; 24: 778-83.
11. Louis R, Lau LCK, Bron AO, Roldaan AC, Radermecker M, Djukanovic R. The relationship between airways inflammation and asthma severity. Am. J. Respir. Crit. Care Med. 2000; 161: 9-16.
12. O'Byrne PM, Postma DS. The many faces of airway inflammation. Asthma and chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1999; 159: S41-63.
13. Pizzichini MM, Popov TA, Efthimiadis A et al. Spontaneous and induced sputum to measure indices of airway inflammation in asthma. Am. J. Respir. Crit. Care Med. 1996; 154: 866-9.
14. Grootendorst DC, van den Bos J-W, Romeijn JJ et al. Induced sputum in adolescents with severe stable asthma. Safety and the relationship of cell counts and eosinophil cationic protein to clinical severity. Eur. Respir. J. 1999; 13: 647-53.
15. van Rensen ELJ, Straathof KCM, Veselic-Charvat MA, Zwinderman AH, Bel EH, Sterk PJ. Effect of inhaled steroids on airway hyperresponsiveness, sputum eosinophils, and exhaled nitric oxide levels in patients with asthma. Thorax 1999; 54: 403-8.
16. Lim S, Jatakanon A, John M et al. Effect of inhaled budesonide on lung function and airway inflammation. Assessment by various inflammatory markers in mild asthma. Am. J. Respir. Crit. Care Med. 1999; 159: 22-30.
17. Claman DM, Boushey HA, Liu J, Wong H, Fahy JV. Analysis of induced sputum to examine the effects of prednisone on airway inflammation in asthmatic subjects. J. Allergy Clin. Immunol. 1994; 94: 861-9.
18. Horiguchi T, Tachikawa S, Kasahara J et al. Suppression of airway inflammation by theophylline in adult bronchial asthma. Respiration 1999; 66: 124-7.
19. Tohda Y, Muraki M, Iwanaga T, Kubo H, Fukuoka M, Nakajima S. The effect of theophylline on blood and sputum eosinophils and ECP in patients with bronchial asthma. Int. J. Immunopharmacol. 1998; 20: 173-81.
20. Pizzichini E, Leff JA, Reiss TF et al. Montelukast reduces airway eosinophilic inflammation in asthma: a randomized, controlled trial. Eur. Respir. J. 1999; 14: 12-18.
21. Sorva R, Metso T, Turpeinen M, Juntunen-Backman K, Bjorksten F, Haahtela T. Eosinophil cationic protein in induced sputum as a marker of inflammation in asthmatic children. Pediatr. Allergy Immunol. 1997; 8: 45-50.
22. Tukiainen H, Taivainen A, Majander R et al. Comparison of high and low dose of the inhaled steroid, budesonide, as an initial treatment in newly detected asthma. Respir. Med. 2000; 94: 678-83.
23. Bacci E, Cianchetti S, Ruocco L et al. Comparison between eosinophilic markers in induced sputum and blood in asthmatic patients. Clin. Exp. Allergy 1998; 28: 1237-43.
24. Grebski E, Wu J, Wuthrich B, Medici TC. Does eosinophil cationic protein in sputum and blood reflect bronchial inflammation and obstruction in allergic asthmatics? J. Invest. Allergol. Clin. Immunol. 1999; 9: 82-8.
25. Pedersen B, Dahl R, Karlstrom R, Peterson CG, Venge P. Eosinophil and neutrophil activity in asthma in a one-year trial with inhaled budesonide. The impact of smoking. Am. J. Respir. Crit. Care Med. 1996; 153: 1519-29.
26. Jarvis B, Faulds D. Inhaled fluticasone propionate: a review of its therapeutic efficacy at dosages < or = 500 microgram/day in adults and adolescents with mild to moderate asthma. Drugs 1999; 57: 769-803.
27. Bleecker ER, Welch MJ, Weinstein SF et al. Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma. J. Allergy Clin. Immunol 2000; 105: 1123-9.
28. Spector SL, Smith LJ, Glass M. Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. ACCOLATE Asthma Trialists Group. Am. J. Respir. Crit. Care Med. 1994; 150: 618-23.
29. Tashkin DP, Nathan RA, Rowland WC, Minkwitz MC, Bonuccelli CM. Efficacy of zafirlukast (Accolate): exploratory subset data from three 13-week multicenter trials. Am. J. Respir. Crit. Care Med. 1997; 155: A663.
30. Nathan RA, Bernstein JA, Bielory L et al. Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction. J. Allergy Clin. Immunol. 1998; 102: 935-42.
31. Suissa S, Dennis R, Ernst P, Sheehy O, Wood-Dauphinee S. Effectiveness of the leukotriene receptor antagonist zafirlukast for mild-to-moderate asthma. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 1997; 126: 177-83.
32. Morali T, Yilmaz A, Erkan F, Akkaya E, Ece F, Baran R. Efficacy of inhaled budesonide and oral theophylline in asthmatic subjects. J. Asthma 2001; 38: 673-9.
33. Leigh R, Vethanayagam D, Yoshida M et al. Effects of montelukast and budesonide on airway responses and airway inflammation in asthma. Am. J. Respir. Crit. Care Med. 2002; 166: 1212-17.